Previous 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Reviva Pharmaceuticals (NASDAQ: RVPH ) and RVPH stock are seeing explosive gains of more than 90% at the time of writing. Source: Shutterstock Today’s move nearly doub...
Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) more than doubled in value Monday after the clinical-stage biopharmaceutical company reported encouraging phase 2 clinical trial results for its lead drug candidate. Positive trial results: Possibility for ȁ...
Gainers: Reviva Pharmaceuticals (RVPH) +85%.Proofpoint (PFPT) +31%.Jiayin Group (JFIN) +31%.MicroVision (MVIS) +31%.Casper Sleep (CSPR) +26%.X Financial (XYF) +25%.Ocugen (OCGN) +24%.Asensus Surgical (ASXC) +22%.Voyager Therapeutics (VYGR) +22%.Dunxin Financial (DXF) +21%.Losers: Fo...
Reviva Pharmaceuticals Holdings (RVPH) announces the full details of its Phase 2 clinical trial for its lead drug candidate, RP5063 (brilaroxazine) for Acute Schizophrenia. In its Phase 2 trial to assess the safety and efficacy of brilaroxazine in 234 subjects, brilaroxazine met its primary e...
Met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder Met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia Mitigated positive symptoms a...
Reviva Pharmaceuticals (RVPH): FY GAAP EPS of -$1.24.Cash and cash equivalents totaled ~$8.8MPress Release For further details see: Reviva Pharmaceuticals reports FY results
-Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market - -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved- CUPERTINO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmace...
CUPERTINO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva”) today announced that its wholly owned subsidiary Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing ...
News, Short Squeeze, Breakout and More Instantly...
Reviva Pharmaceuticals Holdings Inc. Company Name:
RVPH Stock Symbol:
NASDAQ Market:
Reviva Pharmaceuticals Holdings Inc. Website:
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also been granted in k...
2024-06-11 08:15:03 ET H.C. Wainwright analyst issues BUY recommendation for RVPH on June 11, 2024 06:40AM ET. The previous analyst recommendation was Buy. RVPH was trading at $1.45 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...